Current practice is to monitor prothrombin time as an indicator of vitamin K sufficiency in cholestatic liver disease. Since prothrombin time is a surrogate marker, it may underestimate the actual prevalence of vitamin K deficiency in this population. This study investigates the frequency of vitamin K deficiency among a convenience sample of children and adults with cholestatic liver disease by determining plasma levels of protein Plasma PIVKA-II concentrations were measured using a commercially available ELISA kit. Results: 31 subjects were enrolled (age range 0.5-54 years). Nine subjects (29%) had prolonged prothrombin times, while 21 (68%) had elevated PIVKA-II levels. All patients with prolonged PT had PIVKA-II elevations. Of the 21 patients with PIVKA-II elevation, 15 were on supplemental vitamin K therapy (range 7.8-700 µg/kg/day).
at presentation stressing the importance of early supplementation to help prevent longterm consequences. [1] [2] [3] [4] Vitamin K is present naturally as phylloquinones synthesized by green plants and menaquinones produced by intestinal bacteria. Dietary phylloquinones provide the main source of vitamin K in humans and, like other fat-soluble vitamins, require incorporation into micelles within the intestinal lumen for adequate absorption. Vitamin K is rapidly metabolized so malabsorption may lead to rapid depletion of limited stores, leading to clinically significant deficiency. Vitamin K serves as a cofactor for the enzyme γ-glutamylcarboxylase, which is involved in the post-translational carboxylation of glutamic acid residues in many proteins, including coagulation factors such as factors II (prothrombin), VII, IX, X, protein C, protein S, and proteins involved in bone homeostasis, specifically osteocalcin and matrix Gla protein. Most of these proteins are multiply carboxylated, and these carboxylated glutamic acid residues have the ability to bind calcium, making these proteins functionally active. 
Methods
Study Design: This is a cross-sectional study of patients with cholestatic liver disease. were measured using standard laboratory techniques. PIVKA-II concentrations were measured using a commercially available enzyme-linked immunosorbent assay kit (Diagnostica Stago; Asnier, France). This assay uses a mouse monoclonal antibody specific for undercarboxylated prothrombin, but without cross-reactivity to fully carboxylated prothrombin. The assay was standardized at our institution by using discarded plasma from previously stored samples with all identifiers stripped and by recruitment of healthy adults to serve as controls. The lowest limit of detection for this assay is 2 ng/mL. Values of less than 2 ng/mL are considered normal; however, for the purposes of this research protocol, values less than two times the lower limit of detection (4 ng/mL) were considered normal. All control samples fell greater than two standard deviations below this value. All PIVKA-II samples were run in duplicate on two separate days. Within our institution, intraassay variability was 6.2% and interassay variability was 10%. Additional blood was collected for measurement of undercarboxylated osteocalcin. Cumulative blood drawn was 20 mL, which was less than 5% of subjects total blood volume based on subject's weight greater than 6 kilograms. laboratory values below the limit of detection for a particular assay were recorded as the lowest value for that assay. For example, the lowest limit of detection for the Vitamin E assay is 3 ug/mL, therefore, values < 3 ug/mL were recorded as 3 ug/mL. All p-values were two-sided.
Results
Thirty-six patients were enrolled in this study. Two patients (one with biliary atresia, one with idiopathic cholestasis) withdrew due to difficulty obtaining a sufficient quantity of blood for study laboratories. Three additional patients were ineligible based on inclusion/exclusion criteria (1 subject with history of necrotizing enterocolitis and small bowel resection, 2 subjects with biliary atresia did not meet eligibility requirements for cholestasis based on conjugated bilirubin or serum bile acid levels). Of the 31 subjects who fulfilled eligibility criteria, 24 were children (<18 years old) and 7 were adults. Seventeen subjects were female. The most common diagnoses were Alagille's syndrome and biliary atresia, with 10 and 9 subjects respectively, accounting for 60% of the study population. Other diagnoses included primary biliary cirrhosis (4), Progressive
Familial Intrahepatic Cholestasis (2), congenital hepatic fibrosis (1), primary sclerosing cholangitis (1), α-1 antitrypsin deficiency (1), hepatitis C (1) and idiopathic cholestasis (2) . The mean age of the study subjects was 12.8 years (median 5.7, range 0.7-54.1 years) ( Table 2) . Mean serum conjugated bilirubin and bile acids were 1.8 mg/dL and 276 µmol/L, respectively. When pediatric and adult data were separated, there was a trend for the pediatric subject to be more cholestatic, with higher mean serum conjugated bilirubin, alkaline phosphatase, and bile acids. Other laboratory values for study subjects are listed in Table 2 . Of the 31 subjects, 28 had all laboratories drawn at the time of study enrollment.
Three patients did not have prothrombin time or INR results available on the day of study due to insufficient quantity of blood for PT/INR analysis (1 subject) and clotting of the prothrombin sample (2 subjects). One of these subjects had a prothrombin time and INR obtained two days after initial laboratory assessment and this value was used in the analysis. Laboratory records were reviewed for the other two subjects. Both subjects had normal PT/INR before and after study laboratories and a stable medical history without change in medications or clinical status. For these subjects, the prothrombin time and INR values obtained closest to the time of study enrollment were used for analysis. Of the 31 subjects, 9 (29%) had elevated prothrombin times, defined as greater than 13.3 seconds ( Table 3 , Table 4 ). Most prothrombin times were mildly elevated with only 3 values being greater than 15 seconds, with the most prolonged prothrombin time being 21.6 seconds. Twenty-one subjects (68%) had an elevated (abnormal) PIVKA-II, defined as greater than 4 ng/mL ( Table 3, Table 4 ). All subjects with prolongation of their prothrombin times had elevated PIVKA-II values. The highest PIVKA-II value of 5831.4 ng/mL was observed in a pediatric patient with Alagille's. This subject also had the most prolonged prothrombin time and was on supplement vitamin K therapy at a dosage of 162.3 µg/kg/day at the time of study enrollment. Of the 21 subjects with PIVKA-II elevation, 15 (71%) were on supplemental vitamin K therapy, with dosages ranging from 7.8 to 700 µg/kg/day. In subjects with normal PIVKA-II levels, 9 (90%) were on supplemental vitamin K therapy (dosage range 10-289 µg/kg/day). Seven patients (6 adults, 1 child) had no supplemental vitamin K intake. Within this subgroup, 6 (86%) had elevated PIVKA-II levels.
Other fat-soluble vitamin deficiencies were observed in 35% of the study participants. The most common was Vitamin A deficiency, observed in 7 (22.5%) of subjects ( Table 3) . Five subjects (16%) had decreased serum 25-hydroxyvitamin D levels, whereas 2 subjects (8%) had decreased serum Vitamin E levels ( Table 3) . One subject, a pediatric patient with idiopathic cholestasis, had both Vitamin D and Vitamin E deficiency, while two subjects, a pediatric patient with biliary atresia and an adult patient with primary sclerosing cholangitis, had Vitamin D and Vitamin A deficiency. In total, 43% of subjects with Vitamin A deficiency and 100% of subjects with Vitamin D and E deficiency had elevated PIVKA-II values. Table 5 ). As the majority of subjects (77%) were on some form of vitamin K therapy, Spearman correlations were also determined between supplemental vitamin K intake and other measured parameters. Vitamin K intake was positively correlated with serum bile acids and alkaline phosphatase, and the correlation between vitamin K intake and conjugated bilirubin approach significance (Table 6) , indicating patients with more significant cholestatic liver disease were more likely to be on higher dosages of supplemental vitamin K. However, no significant correlation was observed between vitamin K intake and prothrombin time or PIVKA-II levels ( Table 6 ). Subsequently, Spearman correlations between PIVKA-II and other laboratories were re-analyzed, controlling for vitamin K intake. Apart from the correlation between PIVKA-II and alkaline phosphatase, all previously correlated parameters persisted, with the correlations between PIVKA-II and conjugated bilirubin and bile acids remaining most significant ( Table 7) . 22, 23 The measurement of the ratio of serum vitamin E to total lipids is a more accurate indicator of vitamin E status 23 , and as serum total lipids were not measured in our study, vitamin E deficiency may be underestimated in our study population. Since neither serum cholesterol, triglycerides or total lipids were measured in this study, it is unclear how large an impact the presence of hyperlipidemia might have had on serum vitamin E levels. Additionally, in the present study, vitamin A deficiency may be overestimated in our population because vitamin A levels were not normalized for serum retinol binding protein concentrations. In the presence of advanced liver disease, the major transport protein for vitamin A, retinol binding protein, may be reduced, and therefore, some investigators have suggested that the molar ratio of vitamin A to retinol binding protein may better reflect vitamin A sufficiency. 24 Since few patients had evidence of advanced hepatic decompensation as assessed by reduced serum albumin concentrations, this may not represent a significant problem in our study population.
Previous studies have found positive associations between vitamin K deficiency, either measured by low plasma vitamin K levels 14 or elevated undercarboxylated prothrombin 12, 15 , and the severity of cholestasis as determined by elevated conjugated bilirubin, serum bile acids and alkaline phosphatase. This study confirmed these findings, and in addition we identified correlations between PIVKA-II and serum aminotransferases. Since PIVKA-II may be elevated in hepatocarcinoma [25] [26] [27] , the correlation between PIVKA-II and markers of liver cell injury raises the question of whether the PIVKA-II elevation found in our study may have been due to liver inflammation with impaired γ-glutamylcarboxylase rather than deficiency of vitamin K, a cofactor for this enzyme. In fact, patients with non-cholestatic liver disease may have either normal 15, 26 or elevated 26, 27 PIVKA-II levels. In the present study, the 100% concordance between prolonged prothrombin times and elevated PIVKA-II levels and the presence of other fat-soluble vitamin deficiencies in 33% of the subjects with PIVKA-II elevation, strongly suggest that the abnormal PIVKA-II levels were the result of vitamin K deficiency.
Although dietary intake was not assessed, supplemental vitamin K intake was quantified. Not surprisingly, vitamin K intake was positively correlated with the severity of cholestasis suggesting that clinicians recommend supplementation in the presence of increasing cholestasis; however, PIVKA-II elevation was common in these patients despite vitamin K therapy. It would be expected that negative correlations of vitamin K intake with prothrombin time and PIVKA-II levels would be identified; but in fact, there was no correlation among these parameters. This suggests that even with supplementation, intake is not sufficient to overcome the absorptive defect in these patients and current practices of oral vitamin K supplementation may be inadequate to maintain vitamin K nutriture in cholestatic liver disease. A mixed micellar preparation of vitamin K 1 now is available (Kanakion MM) in Europe, but unfortunately, absorption of this formulation in cholestatic infants remains poor and unpredictable. 28 In addition, few clinicians recommend parenteral vitamin K unless extremely prolonged prothrombin times develop. Future studies examining the dosage and route of vitamin K administration are therefore indicated.
This study evaluated subjects with a variety of cholestatic conditions and had a large proportion of pediatric patients, a subgroup for whom data on vitamin K deficiency is lacking. However, one limitation of this study is the sample size, particularly in regards to the adult population. Clinical characteristics and medical management may differ between adult and pediatric subjects. In the present study, there was a trend for the pediatric patients to be more cholestatic, with higher conjugated bilirubin and serum bile acids, factors that are highly correlated with PIVKA-II elevation. Additionally, pediatric patients were more likely to be on supplemental vitamin K replacement. Only one adult subject, a patient with Alagille's Syndrome followed at the pediatric center, was on vitamin K therapy. Although the study had significant power to evaluate correlations between PIVKA-II and markers of cholestasis within the study population, differences between various cholestatic conditions and adult and pediatric subjects and predictors of PIVKA-II elevation within these subgroups could not be assessed. A second limitation of this study might be whether the results from this small group of children and adults with cholestasis would be generalizable to a larger group of patients. There is, however, no reason to believe that our subjects would not be representative of all pediatric and adult cholestatic patients.
In summary, despite supplementation, vitamin K deficiency, as determined by elevated PIVKA-II levels, is common in cholestatic liver disease and frequently accompanies other fat-soluble vitamin deficiencies. Patients with advanced cholestasis, with high conjugated bilirubin and serum bile acids, are at highest risk for vitamin K deficiency. Prothrombin time underestimates the prevalence, and better strategies for vitamin K assessment and guidelines for specific dosing in cholestatic liver disease should be developed.
